TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12173383

Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy (20 Gy/5 days)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Surgery alone (Control group)
Number of subjects: 102
Study: 10100044

Group type: EXPERIMENTAL
Intervention: Toothbrushing with water
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Chewing gum
Number of subjects: 3

Group type: COMPARATOR
Intervention: No chewing gum
Number of subjects: 3

Group type: COMPARATOR
Intervention: No toothbrushing
Number of subjects: 3
Study: 7608317

Group type: EXPERIMENTAL
Intervention: Roferon-A reconstituted with 10 mg of HSA
Number of subjects: 24

Group type: COMPARATOR
Intervention: Roferon-A reconstituted with HSA-free diluent
Number of subjects: 24
Study: 1978736

Group type: EXPERIMENTAL
Intervention: Fenoldopam (FD) at doses from 0.05 to 0.50 micrograms/kg/min
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Fenoldopam (FD) combined with Metoclopramide (MCP)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Metoclopramide (MCP)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 328540

Group type: EXPERIMENTAL
Intervention: Spironolactone and hydrochlorothiazide combination therapy
Number of subjects: 32

Group type: COMPARATOR
Intervention: Furosemide
Number of subjects: 32
Study: 30723739

Group type: EXPERIMENTAL
Intervention: Combined training of the pelvic floor muscles (PFM) and the transversus abdominis (TrA) muscle (Group A)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Isolated pelvic floor muscles exercises (Group B)
Number of subjects: 137
Study: 29243273

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) therapy for nonsleepy OSA patients (n = 122)
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) therapy for sleepy OSA patients (n = 155)
Number of subjects: 277
Study: 25656133

Group type: EXPERIMENTAL
Intervention: 1% polar sunflower seed oil
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: 10% polar glyceryl trioleate
Number of subjects: 3

Group type: COMPARATOR
Intervention: 1% non-polar mineral oil
Number of subjects: 3

Group type: COMPARATOR
Intervention: 10% non-polar dodecane
Number of subjects: 3
Study: 24531742

Group type: EXPERIMENTAL
Intervention: Resistance Exercise Training (RET)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Training (AET)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Both RET and AET
Number of subjects: 26
Study: 23017308

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation
Number of subjects: 51
Study: 19716598

Group type: EXPERIMENTAL
Intervention: Tiotropium (18 microg once daily)
Number of subjects: 2739

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 2739
Study: 17475734

Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 1439

Group type: EXPERIMENTAL
Intervention: Switch strategy
Number of subjects: 1439

Group type: COMPARATOR
Intervention: Augmentation strategy
Number of subjects: 1439
Study: 15186737

Group type: EXPERIMENTAL
Intervention: Interferon-alpha 2b, cyclophosphamide, and prednisone as maintenance therapy
Number of subjects: 169

Group type: COMPARATOR
Intervention: Control group (no maintenance therapy)
Number of subjects: 169
Study: 15143717

Group type: EXPERIMENTAL
Intervention: Jiangtang Bushen Recipe (JBR) in addition to dietotherapy and kinetotherapy
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (dietotherapy and kinetotherapy only)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: TCM group (JBR)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: TCM group
Number of subjects: 51
Study: 11297816

Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg over 60 min)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 9043726

Group type: EXPERIMENTAL
Intervention: Lorazepam (0.03 mg.kg‐1 sl), morphine (0.15 mg.kg‐1 im), and perphenazine (0.05 mg.kg‐1 im)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Lorazepam (0.03 mg.kg‐1 sl) and saline (1.5 ml im)
Number of subjects: 68
Study: 7709624

Group type: EXPERIMENTAL
Intervention: Single procedure of manual therapy
Number of subjects: 46
Study: 3108586

Group type: EXPERIMENTAL
Intervention: Hydroxyurea plus pelvic radiation
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo plus pelvic radiation
Number of subjects: 45
Study: 30037355

Group type: EXPERIMENTAL
Intervention: 5-day preoperative decolonization bundle (nasal mupirocin, chlorhexidine gluconate bathing, and chlorhexidine mouthwash)
Number of subjects: 110

Group type: COMPARATOR
Intervention: 2 preoperative showers with antiseptic soap (control)
Number of subjects: 110
Study: 28207529

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine without loading dose (PRDo)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Propofol/remifentanil/Ringer solution (PRR)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine with loading dose (PRDw)
Number of subjects: 70
Study: 25731985

Group type: EXPERIMENTAL
Intervention: Chimpanzees (Pan troglodytes)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baboons (Papio papio)
Number of subjects: 0
Study: 23192756

Group type: EXPERIMENTAL
Intervention: Cardionet mobile cardiac outpatient telemetry monitor for 21 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Routine follow-up alone
Number of subjects: 40
Study: 21509720

Group type: EXPERIMENTAL
Intervention: Nitroglycerin added to cardioplegia
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (no nitroglycerin)
Number of subjects: 60
Study: 18280850

Group type: EXPERIMENTAL
Intervention: Needle-free powder lidocaine delivery system
Number of subjects: 306

Group type: COMPARATOR
Intervention: Sham placebo
Number of subjects: 306
Study: 17315426

Group type: EXPERIMENTAL
Intervention: Patient-controlled epidural analgesia with pethidine (25 mg of five mg/ml solution, lockout of 10 minutes, maximum dose of 150 mg/four hours)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Nurse-administered epidural pethidine (bolus of 50 mg, maximum dose of 50 mg/two hours)
Number of subjects: 34
Study: 14626183

Group type: EXPERIMENTAL
Intervention: Astragalus injection (AI) combined with chemotherapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Chemotherapy alone (control group)
Number of subjects: 60
Study: 10930183

Group type: EXPERIMENTAL
Intervention: P592S mutation
Number of subjects: 803

Group type: COMPARATOR
Intervention: T594M mutation
Number of subjects: 803
Study: 8962554

Group type: EXPERIMENTAL
Intervention: LDL apheresis plus simvastatin
Number of subjects: 42

Group type: COMPARATOR
Intervention: Medication alone (simvastatin)
Number of subjects: 42
Study: 14621717

Group type: EXPERIMENTAL
Intervention: CSA/AZA
Number of subjects: 44

Group type: COMPARATOR
Intervention: Prednisone
Number of subjects: 44
Study: 3842611

Group type: EXPERIMENTAL
Intervention: Hexabrix 320
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Iopamiro 370
Number of subjects: 77

Group type: COMPARATOR
Intervention: Urovison
Number of subjects: 77

Group type: COMPARATOR
Intervention: Urografin
Number of subjects: 77

Group type: COMPARATOR
Intervention: All contrast agents
Number of subjects: 77
Study: 30815731

Group type: EXPERIMENTAL
Intervention: 2.5% NaOCl + QMix + EndoActivator (G4)
Number of subjects: 104

Group type: COMPARATOR
Intervention: 2.5% NaOCl + EndoActivator (G2)
Number of subjects: 104

Group type: COMPARATOR
Intervention: 2.5% NaOCl + QMix + conventional endodontic syringe (G3)
Number of subjects: 104

Group type: COMPARATOR
Intervention: 2.5% NaOCl + conventional endodontic syringe (G1)
Number of subjects: 104
Study: 27791254

Group type: EXPERIMENTAL
Intervention: AGV with adjunctive triamcinolone (TA group)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Conventional AGV (non-TA group)
Number of subjects: 90
Study: 25684073

Group type: EXPERIMENTAL
Intervention: Explicit instruction to consider non-health-related utility in TTO exercises
Number of subjects: 104

Group type: COMPARATOR
Intervention: No explicit instruction for the consideration of consumption and leisure effects in TTO exercise
Number of subjects: 104
Study: 24686255

Group type: EXPERIMENTAL
Intervention: Fasinumab 0.03 mg/kg
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Fasinumab 0.1 mg/kg
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Fasinumab 0.3 mg/kg
Number of subjects: 217

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 217
Study: 21986695

Group type: EXPERIMENTAL
Intervention: Cold Water Immersion (CWI)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (quiet sitting)
Number of subjects: 22
Study: 19443679

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg and Ezetimibe 10 mg
Number of subjects: 90
Study: 17877648

Group type: EXPERIMENTAL
Intervention: Inhaled human insulin (Exubera; EXU)
Number of subjects: 922

Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 922

Group type: COMPARATOR
Intervention: Sulphonylurea (glibenclamide)
Number of subjects: 922
Study: 15077226

Group type: EXPERIMENTAL
Intervention: Amifostine (740 mg/m2 for 2 doses preceding BCNU)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study: 12453890

Group type: EXPERIMENTAL
Intervention: 0.3 mU · kg1 · min‐1 insulin infusion
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 8
Study: 10209349

Group type: EXPERIMENTAL
Intervention: Sumatriptan nasal spray 5 mg
Number of subjects: 544

Group type: EXPERIMENTAL
Intervention: Sumatriptan nasal spray 10 mg
Number of subjects: 544

Group type: EXPERIMENTAL
Intervention: Sumatriptan nasal spray 20 mg
Number of subjects: 544

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 544
Study: 7585287

Group type: EXPERIMENTAL
Intervention: High protein diet (11% of total energy from protein for group MH, 17% for group FH, 10% for group NL)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: High protein diet
Number of subjects: 21
Study: 2246576

Group type: EXPERIMENTAL
Intervention: Rifampicin systemically
Number of subjects: 25

Group type: COMPARATOR
Intervention: Rifampicin locally (ointment)
Number of subjects: 25
Study: 6446852

Group type: EXPERIMENTAL
Intervention: Immediate Treatment Group (Acupuncture)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Delayed Treatment Group (Acupuncture after initial control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both treatment groups (Immediate and Delayed Treatment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inadequate Treatment Group (Control)
Number of subjects: 0
Study: 6403280

Group type: EXPERIMENTAL
Intervention: CO2-rebreathing method
Number of subjects: 50
Study: 30124729

Group type: EXPERIMENTAL
Intervention: SB208 4%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pooled SB208-treated groups
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 0
Study: 26115978

Group type: EXPERIMENTAL
Intervention: Irinotecan plus cisplatin (NACT group)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Paclitaxel plus cisplatin (TP group)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Control group (direct surgery, DS group)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Irinotecan plus cisplatin (IP group)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: NACT (irinotecan plus cisplatin or paclitaxel plus cisplatin)
Number of subjects: 219
Study: 24933106

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 22684355

Group type: EXPERIMENTAL
Intervention: Budesonide 400 mcg twice daily
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study: 20332245

Group type: EXPERIMENTAL
Intervention: GH therapy for 4 months (36 microg/kg x d)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Delayed start of GH therapy (untreated for 4 months, then GH for 4 months)
Number of subjects: 35
Study: 18564796

Group type: EXPERIMENTAL
Intervention: Ephedrine (initial dose 50 mg infused over 30 minutes, dose intervals of 5 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mephentermine (initial dose 50 mg infused over 30 minutes, dose intervals of 5 mg)
Number of subjects: 0
Study: 15373702

Group type: EXPERIMENTAL
Intervention: H. pylori eradication (treated with omeprazole and antibiotics)
Number of subjects: 1108

Group type: EXPERIMENTAL
Intervention: H. pylori eradication
Number of subjects: 1108

Group type: COMPARATOR
Intervention: No treatment (untreated group)
Number of subjects: 1108

Group type: EXPERIMENTAL
Intervention: Participants without gastric atrophy, intestinal metaplasia, and dysplasia
Number of subjects: 1108
Study: 11197291

Group type: EXPERIMENTAL
Intervention: Electrogastrography (EGG)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Gastric emptying of radiopaque pellets
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Gastroscopy
Number of subjects: 22
Study: 9136213

Group type: EXPERIMENTAL
Intervention: Multiple objective tests for hand-arm vibration syndrome
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cold provocation testing
Number of subjects: 0
Study: 8195678

Group type: EXPERIMENTAL
Intervention: Prinomide (1500 mg/day)
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Naproxen (1500 mg/day)
Number of subjects: 267

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 267
Study: 2977043

Group type: EXPERIMENTAL
Intervention: Oral dose of 3 X 100 mg MPA
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Weekly changing scheme with 2 X 10 mg Tamoxifen and 3 X 100 mg MPA
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Oral dose of 1000 mg MPA daily (in 4 patients with ovarian carcinoma)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cortisol concentration measured at the same time
Number of subjects: 40
Study: 28986606

Group type: EXPERIMENTAL
Intervention: Breviscapine (120 mg daily, 40 mg three times a day for 14 days)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 25344059

Group type: EXPERIMENTAL
Intervention: Healthy Eating and Exercise Lifestyle Program
Number of subjects: 134

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 134
Study: 25241373

Group type: EXPERIMENTAL
Intervention: Question wording asking if pregnancies were planned or wanted
Number of subjects: 8575

Group type: EXPERIMENTAL
Intervention: Question wording with additional information on reasons for not using contraception
Number of subjects: 8575

Group type: EXPERIMENTAL
Intervention: Multivariate analysis comparing unplanned vs unwanted pregnancies
Number of subjects: 8575
Study: 22713347

Group type: EXPERIMENTAL
Intervention: Community member providing As education and WAs testing
Number of subjects: 100

Group type: COMPARATOR
Intervention: Outside representative performing As education and WAs testing
Number of subjects: 100
Study: 20559656

Group type: EXPERIMENTAL
Intervention: Pentavalent rotavirus vaccine (RV5)
Number of subjects: 23000
Study: 17010994

Group type: EXPERIMENTAL
Intervention: Olanzapine treatment (10-20mg/day)
Number of subjects: 271
Study: 16234007

Group type: EXPERIMENTAL
Intervention: Alvimopan 12 mg twice daily with placebo
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Alvimopan 12 mg twice daily with codeine 30 mg 4 times/day
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo with codeine 30 mg 4 times/day
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo with placebo
Number of subjects: 74
Study: 12483729

Group type: EXPERIMENTAL
Intervention: IDEC‐131 (2.5 mg/kg to 10.0 mg/kg)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study: 9690596

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia (2 mL 0.5% dibucaine)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Epidural anesthesia (20 mL 2% mepivacaine)
Number of subjects: 30
Study: 8279421

Group type: EXPERIMENTAL
Intervention: 4-day diet record (FDDR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fat-related diet-habits questionnaire
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Food-frequency questionnaire (FFQ)
Number of subjects: 0
Study: 2686547

Group type: EXPERIMENTAL
Intervention: norfloxacin (400 mg three times a day)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: pefloxacin (400 mg three times a day)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: norfloxacin and pefloxacin
Number of subjects: 10
Study: 4425916

Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 20
Study: 31999316

Group type: COMPARATOR
Intervention: text-only visualization
Number of subjects: 40

Group type: COMPARATOR
Intervention: line graph visualization
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: visual analogy visualization
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: number line visualization
Number of subjects: 40
Study: 30480860

Group type: EXPERIMENTAL
Intervention: Active sTMS
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Active sTMS (10 weeks)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Open/active phase sTMS
Number of subjects: 120
Study: 27564925

Group type: EXPERIMENTAL
Intervention: Laser therapy (λ of 640 nm and SAEF of 1.06 J/cm2)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: LED therapy (λ of 660 ± 20 nm and SAEF of 0.24 J/cm2)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 120
Study: 27383132

Group type: EXPERIMENTAL
Intervention: RombergLab software using a low cost force platform
Number of subjects: 20

Group type: COMPARATOR
Intervention: Clinical approved software and force platform
Number of subjects: 20
Study: 25187339

Group type: EXPERIMENTAL
Intervention: Pharmacist Group (PG)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Nurse Group (NG)
Number of subjects: 201
Study: 22033367

Group type: EXPERIMENTAL
Intervention: Active warm-up (10 minutes of stationary cycling at 70% of predicted maximum heart rate)
Number of subjects: 21

Group type: COMPARATOR
Intervention: No warm-up (sat quietly)
Number of subjects: 21
Study: 18842959

Group type: EXPERIMENTAL
Intervention: Treatment group with personally relevant statement
Number of subjects: 173

Group type: COMPARATOR
Intervention: Control group without personally relevant statement
Number of subjects: 173
Study: 17257479

Group type: EXPERIMENTAL
Intervention: Oral linezolid during hospitalization and after discharge
Number of subjects: 3

Group type: COMPARATOR
Intervention: IV vancomycin/oral linezolid switch
Number of subjects: 3

Group type: COMPARATOR
Intervention: IV vancomycin
Number of subjects: 3
Study: 15165660

Group type: EXPERIMENTAL
Intervention: Mailing FOBT cards and reminders 2 weeks prior to a scheduled appointment
Number of subjects: 119

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 119
Study: 11586040

Group type: EXPERIMENTAL
Intervention: IUD not removed, treated with trimethoprim and sulfamethoxazole
Number of subjects: 43

Group type: COMPARATOR
Intervention: IUD removed, treated with trimethoprim and sulfamethoxazole
Number of subjects: 43
Study: 10442373

Group type: EXPERIMENTAL
Intervention: Uracil/tegafur (UFT) 250 mg/m2/day plus oral calcium folinate 45 mg/day
Number of subjects: 0
Study: 7599544

Group type: EXPERIMENTAL
Intervention: Sufentanil with bupivacaine
Number of subjects: 54

Group type: COMPARATOR
Intervention: Fentanyl with bupivacaine
Number of subjects: 54
Study: 2213107

Group type: EXPERIMENTAL
Intervention: Beta-carotene (30 mg/d)
Number of subjects: 24

Group type: COMPARATOR
Intervention: 13-cis retinoic acid (1 mg/kg/d)
Number of subjects: 24
Study: 859784

Group type: EXPERIMENTAL
Intervention: Dextran-70
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Low-dose heparin
Number of subjects: 100
Study: 30981653

Group type: EXPERIMENTAL
Intervention: Pre-deployment training for Hajj duties
Number of subjects: 1216

Group type: COMPARATOR
Intervention: Non Hajj HCWs (no pre-deployment training)
Number of subjects: 1216
Study: 28625246

Group type: EXPERIMENTAL
Intervention: High flow hemodialysis (HFHD)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine hemodialysis (HD)
Number of subjects: 60
Study: 25884819

Group type: EXPERIMENTAL
Intervention: Tailored implementation programme
Number of subjects: 444

Group type: COMPARATOR
Intervention: Standardised training and feedback
Number of subjects: 444
Study: 24270457

Group type: EXPERIMENTAL
Intervention: ATM Tabata interval-training program (sprinting on an ATM at 7.5 miles⋅h with front jets turned on at 80, 85, 90, and 95% progressively increasing throughout the 8 weeks)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (CON) which only completed Pre‐ and Posttesting
Number of subjects: 25
Study: 21350025

Group type: EXPERIMENTAL
Intervention: recombinant human IL-6 (rhIL-6) infusion into the peritendinous tissue of the Achilles tendon
Number of subjects: 14

Group type: COMPARATOR
Intervention: exercise group performing a 1-h treadmill run (12 km/h, 2% uphill)
Number of subjects: 14
Study: 19106357

Group type: EXPERIMENTAL
Intervention: High-dose methotrexate (MTX) injected intravascularly at 100 mg/m² plus 200 mg/m² in 500 mL of normal saline solution with folinic acid rescue
Number of subjects: 50

Group type: COMPARATOR
Intervention: Surgical treatment
Number of subjects: 50
Study: 17179377

Group type: EXPERIMENTAL
Intervention: Surgical intervention (n = 13)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Conservative treatment (n = 22)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Intussusception length > 3.5 cm
Number of subjects: 35
Study: 15250831

Group type: EXPERIMENTAL
Intervention: Exfoliative cytology (EC) combined with DNA-image cytometry
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Cytology yielding tumor cell-positive, suspicious, or doubtful results
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: DNA-cytometry
Number of subjects: 98

Group type: COMPARATOR
Intervention: Histology
Number of subjects: 98
Study: 11230464

Group type: EXPERIMENTAL
Intervention: 5 cycles of 4'-epidoxorubicin 60 mg/m² days 1 and 2 and ifosfamide 1.8 g/m² days 1 through 5, with hydration, mesna, and granulocyte colony-stimulating factor
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: 5 cycles of 4'-epidoxorubicin and ifosfamide
Number of subjects: 104